Guidelines

LONDON — Despite the World Health Organization citing immunization as one of the most powerful and cost-effective interventions in public health, a new survey conducted by Ipsos MORI and sponsored by GSK Vaccines in Brazil, Germany, India, Italy and the United States found that 68% of adults are not up-to-date with the vaccines recommended for them.

Almost three in 10 adults report not having had any of the vaccines potentially relevant to them within the past five years.

WASHINGTON — The dietary supplement industry’s leading trade associations and the U.S. Anti-Doping Agency on Wednesday joined in support of the U.S. Food and Drug Administration’s recent actions to protect consumers from body-building products containing Selective Androgen Receptor Modulators (SARMs) illegally marketed as dietary supplements.

LOUISVILLE, Ky. — The State of Ohio Board of Pharmacy is partnering with Appriss Health to bolster the state’s prescription drug monitoring program, the Ohio Automated Rx Reporting System, or OARRS. The reporting system will now offer access to Appriss Health’s NarxCare analytics and patient support platform to pharmacists and prescribers within their clinical workflow and through OARRS.

WOONSOCKET, R.I. — CVS Health is marking American Diabetes Month by emphasizing efforts patients can undertake to manage their conditions, as well as the services the company offers to make diabetes management easier.

The company said patients with diabetes should manage their diet and engage in a healthy lifestyle — including at least 30 minutes of exercise daily — in an effort to manage their blood glucose, blood pressure and cholesterol. CVS pharmacists also can offer information and product suggestions to aid lifestyle management, CVS Health said.

PRINCETON, N.J. — Major portions of the American population with diabetes believe that their care requires much more than medicine, including emotional support and lifestyle management, and that diabetes care reimbursement needs to be broadened, according to a Novo Nordisk survey published Wednesday.

PITTSBURGH — Mylan has introduced its generic of Clolar (clofarabine 1 mg/ml) injection. The drug is indicated to treat patients ages 1 year to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior treatment regimens.

The latest launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products. Mylan’s Clolar generic will be available in single-dose vials.

According to data from IQVIA (formerly QuintilesIMS), the drug had U.S. sales of $53 million for the 12 months ended Sept. 30.
 

GREENVILLE, N.C. — Mayne Pharma’s newest portfolio addition is its generic of Clorazil (clozapine) tablets. The antipsychotic is indicated to treat severely ill patients with schizophrenia and to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.

“The launch of the full range of Clozapine tablets is our sixth product launch in 2017 and will further diversify our product offering,” Mayne Pharma CEO Scott Richards said.